AddLife has acquired Unicam, a Portuguese distributor of laboratory equipment with approximately €10 million in annual revenue, according to Dealroom. The deal puts a concrete number on what is otherwise a familiar pattern in the European life science tools channel: mid-sized distributors with national footprints being absorbed by listed pan-European groups.

The €10 million revenue figure is the single hardest fact in the transaction, and it frames the deal's scale. Unicam operates in a market segment — national distribution of laboratory instrumentation and consumables — where companies of this size typically serve academic institutes, hospital laboratories, and industrial quality-control labs across a single country or language region. Portugal's research infrastructure market is smaller than Spain's or Germany's, which makes a €10 million turnover a meaningful share of the national channel for lab equipment.

For AddLife, the acquisition fits a documented buy-and-build strategy. The Swedish group, listed on Nasdaq Stockholm, has spent more than a decade assembling a portfolio of distribution and diagnostic businesses across the Nordics and, increasingly, continental Europe. Each acquisition of a national distributor adds localized sales capacity, service technicians, and installed-base relationships with instrument vendors — the assets that determine whether a lab keeps buying consumables and service contracts from one channel partner or switches.

R&D managers in Portugal should read this transaction through the lens of procurement continuity. When a national distributor changes owner, the practical questions are contractual: which instrument lines remain in the portfolio, whether service agreements and response-time commitments carry over, and whether pricing terms negotiated under the previous owner survive integration. AddLife's track record with prior distribution acquisitions suggests it retains local operations rather than consolidating them into a single European entity, but lab administrators will want confirmation on service-level terms in writing.

For instrument vendors, the deal changes the map of who controls access to Portuguese labs. Distributors with €10 million in revenue typically represent a roster of international manufacturers under exclusive or semi-exclusive national agreements. AddLife's ownership may reshape which vendors gain priority in that channel — a portfolio decision that manufacturers' European sales directors will now be reviewing.

The financial details beyond Unicam's revenue — purchase price, valuation multiple, earnout structure — were not disclosed in the available reporting. That absence limits what outside analysts can conclude about how AddLife values distribution assets in Southern Europe relative to its Nordic acquisitions. Comparable transactions in the sector have commanded multiples in the mid-single to low-double digits of EBITDA, but applying those benchmarks to Unicam without margin data would be speculation.

What is measured here: a completed acquisition and a €10 million revenue base in Portugal. What is projection: any assumption about synergies, cross-selling of AddLife's existing product lines into Unicam's customer base, or expansion from Portugal into the wider Iberian market. None of that has been quantified in the public record of this deal.

The transaction signals continued consolidation pressure in the European lab supply channel, and further AddLife acquisitions in Southern Europe would confirm whether Portugal is a foothold or a one-off addition.